American Society of Hematology

Figure 5.

$Figure 5. PK11195 can increase GO cytotoxicity in primary AML cell samples. Nine primary cell samples from AML patients who had not yet received GO therapy were exposed to 10 ng/mL GO with or without 50 μM PK11195, 2.5 μg/mL CSA, or 20 μM MK-571. The treated live cell fractions are displayed relative to untreated live cell fractions, as in Figure 2. PK11195 specifically increased GO-induced cytotoxicity in 6 samples, was more than supra-additive with GO in 5 samples, and was more effective than CSA or MK-571 in 4 of these samples. Each primary cell sample was exposed to each treatment condition in triplicate wells.$

PK11195 can increase GO cytotoxicity in primary AML cell samples. Nine primary cell samples from AML patients who had not yet received GO therapy were exposed to 10 ng/mL GO with or without 50 μM PK11195, 2.5 μg/mL CSA, or 20 μM MK-571. The treated live cell fractions are displayed relative to untreated live cell fractions, as in Figure 2. PK11195 specifically increased GO-induced cytotoxicity in 6 samples, was more than supra-additive with GO in 5 samples, and was more effective than CSA or MK-571 in 4 of these samples. Each primary cell sample was exposed to each treatment condition in triplicate wells.

This Feature Is Available To Subscribers Only